Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in lamivudine-resistant hepatitis B patients, tenofovir significantly reduced HBV DNA levels faster and more consistently than adefovir, reaching undetectable levels in all treated patients by 44 weeks.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This observational study suggests that antiretroviral drugs that interact with CYP 3A4 enzymes may alter finasteride's effectiveness for hair loss in men treated for HIV.

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

HIV can cause various nail and hair disorders, important for early diagnosis and treatment.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

In this study of Egyptian patients on hepatitis C treatment, 34% experienced skin-related side effects from sofosbuvir and daclatasvir, such as itching and hyperpigmentation, but most reactions were mild and reversible without needing to stop therapy.

This article reviews the various short- and long-term side effects of antiretroviral therapy for HIV, highlighting issues like dyslipidemia and hypertension, but reports no new clinical results.

This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.

This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

In this study, a 33-year-old HIV-infected man experienced alopecia areata after beginning zidovudine therapy, which reversed upon discontinuation.

In this bibliometric study, researchers analyzed 96 publications from 2000 to 2022 to identify trends in HIV-1 capsid inhibitor research, highlighting the USA as a leading contributor and emphasizing the importance of molecular studies and drug discovery in advancing antiretroviral therapy.

This study identified several gonadal hormone drugs, including toremifene citrate, tamoxifen citrate, and clomiphene citrate, that effectively inhibited filovirus entry in a pseudovirus model.

This study found that using urine tenofovir monitoring for PrEP adherence is well-accepted and may help overcome adherence barriers among participants at a U.S. urban clinical center.

This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.

In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.

In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.

In this case report, researchers highlight a 57-year-old HIV patient on ritonavir who developed Cushing’s syndrome from over-the-counter intranasal fluticasone, underscoring the risks of drug interactions and the importance of counseling patients about potential steroid ingredients in OTC products.

In this study, researchers examined chronic hepatitis B patients and found that those undergoing interferon therapy reported higher quality of life than those on non-antiviral or nucleoside/nucleotide analogue treatments, despite potential side effects.

This study found that Golvatinib, Gliquidone, and Dihydroergotamine may inhibit the binding of SARS-CoV-2's Nsp1 protein to the host ribosomal subunit, suggesting potential as treatments against COVID-19 variants.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

This study reported that a newly formulated Curcumin-loaded proniosome, named F5, exhibited enhanced antiviral efficacy, stability, and safety when compared to Curcumin alone, and improved the therapeutic performance of Acyclovir by reducing its effective dose against Herpes simplex virus.

This study found that recombinant IFN α-2b injections in patients with acute post-transfusion hepatitis C can suppress viral RNA and lead to normalization of serum ALT, though long-term prevention of chronicity remains unclear.

This correspondence reported significant variability between quantitative PCR and bDNA assays for measuring Hepatitis C virus RNA in high-titer specimens, challenging the reliability of the Chiron assay.

This case report highlights that a patient developed alopecia areata following treatment with sofosbuvir and ribavirin for chronic hepatitis C.

This compilation details various potential side effects and interactions of vitamin A, but it reports no new research findings.

This study identified five FDA-approved drugs, including cepharantine and clofazimine, as potential COVID-19 therapies through in silico and in vitro screening targeting viral entry mechanisms.

In this case study, hypertrichosis in a patient with hemophilia and hepatitis C may have been induced by IFN-alpha treatment, despite the drug usually causing hair loss.